Cargando…
Mechanism of diabetic neuropathy: Where are we now and where to go?
Neuropathy is the most common complication of diabetes. As a consequence of longstanding hyperglycemia, a downstream metabolic cascade leads to peripheral nerve injury through an increased flux of the polyol pathway, enhanced advanced glycation end‐products formation, excessive release of cytokines,...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008011/ https://www.ncbi.nlm.nih.gov/pubmed/24843457 http://dx.doi.org/10.1111/j.2040-1124.2010.00070.x |
_version_ | 1782314386809946112 |
---|---|
author | Yagihashi, Soroku Mizukami, Hiroki Sugimoto, Kazuhiro |
author_facet | Yagihashi, Soroku Mizukami, Hiroki Sugimoto, Kazuhiro |
author_sort | Yagihashi, Soroku |
collection | PubMed |
description | Neuropathy is the most common complication of diabetes. As a consequence of longstanding hyperglycemia, a downstream metabolic cascade leads to peripheral nerve injury through an increased flux of the polyol pathway, enhanced advanced glycation end‐products formation, excessive release of cytokines, activation of protein kinase C and exaggerated oxidative stress, as well as other confounding factors. Although these metabolic aberrations are deemed as the main stream for the pathogenesis of diabetic microvascular complications, organ‐specific histological and biochemical characteristics constitute distinct mechanistic processes of neuropathy different from retinopathy or nephropathy. Extremely long axons originating in the small neuronal body are vulnerable on the most distal side as a result of malnutritional axonal support or environmental insults. Sparse vascular supply with impaired autoregulation is likely to cause hypoxic damage in the nerve. Such dual influences exerted by long‐term hyperglycemia are critical for peripheral nerve damage, resulting in distal‐predominant nerve fiber degeneration. More recently, cellular factors derived from the bone marrow also appear to have a strong impact on the development of peripheral nerve pathology. As evident from such complicated processes, inhibition of single metabolic factors might not be sufficient for the treatment of neuropathy, but a combination of several inhibitors might be a promising approach to overcome this serious disorder. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2010.00070.x, 2010) |
format | Online Article Text |
id | pubmed-4008011 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-40080112014-05-19 Mechanism of diabetic neuropathy: Where are we now and where to go? Yagihashi, Soroku Mizukami, Hiroki Sugimoto, Kazuhiro J Diabetes Investig Review Articles Neuropathy is the most common complication of diabetes. As a consequence of longstanding hyperglycemia, a downstream metabolic cascade leads to peripheral nerve injury through an increased flux of the polyol pathway, enhanced advanced glycation end‐products formation, excessive release of cytokines, activation of protein kinase C and exaggerated oxidative stress, as well as other confounding factors. Although these metabolic aberrations are deemed as the main stream for the pathogenesis of diabetic microvascular complications, organ‐specific histological and biochemical characteristics constitute distinct mechanistic processes of neuropathy different from retinopathy or nephropathy. Extremely long axons originating in the small neuronal body are vulnerable on the most distal side as a result of malnutritional axonal support or environmental insults. Sparse vascular supply with impaired autoregulation is likely to cause hypoxic damage in the nerve. Such dual influences exerted by long‐term hyperglycemia are critical for peripheral nerve damage, resulting in distal‐predominant nerve fiber degeneration. More recently, cellular factors derived from the bone marrow also appear to have a strong impact on the development of peripheral nerve pathology. As evident from such complicated processes, inhibition of single metabolic factors might not be sufficient for the treatment of neuropathy, but a combination of several inhibitors might be a promising approach to overcome this serious disorder. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2010.00070.x, 2010) Blackwell Publishing Ltd 2011-01-24 2010-10-06 /pmc/articles/PMC4008011/ /pubmed/24843457 http://dx.doi.org/10.1111/j.2040-1124.2010.00070.x Text en © 2010 Asian Association for the Study of Diabetes and Blackwell Publishing Asia Pty Ltd |
spellingShingle | Review Articles Yagihashi, Soroku Mizukami, Hiroki Sugimoto, Kazuhiro Mechanism of diabetic neuropathy: Where are we now and where to go? |
title | Mechanism of diabetic neuropathy: Where are we now and where to go? |
title_full | Mechanism of diabetic neuropathy: Where are we now and where to go? |
title_fullStr | Mechanism of diabetic neuropathy: Where are we now and where to go? |
title_full_unstemmed | Mechanism of diabetic neuropathy: Where are we now and where to go? |
title_short | Mechanism of diabetic neuropathy: Where are we now and where to go? |
title_sort | mechanism of diabetic neuropathy: where are we now and where to go? |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008011/ https://www.ncbi.nlm.nih.gov/pubmed/24843457 http://dx.doi.org/10.1111/j.2040-1124.2010.00070.x |
work_keys_str_mv | AT yagihashisoroku mechanismofdiabeticneuropathywherearewenowandwheretogo AT mizukamihiroki mechanismofdiabeticneuropathywherearewenowandwheretogo AT sugimotokazuhiro mechanismofdiabeticneuropathywherearewenowandwheretogo |